Fate Therapeutics, Inc. provided earnings guidance for the year 2023. For each of the remaining three quarters of 2023, the Company expects to recognize approximately $0.8 million in revenue under the ONO collaboration in connection with its conduct of preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.165 USD | +0.36% | +8.63% | +12.70% |
10/05 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
10/05 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.70% | 47Cr | |
+4.24% | 11TCr | |
+10.95% | 11TCr | |
-12.08% | 2.23TCr | |
-3.90% | 2.19TCr | |
-5.94% | 1.86TCr | |
-36.52% | 1.81TCr | |
-10.04% | 1.7TCr | |
+2.96% | 1.37TCr | |
+37.30% | 1.24TCr |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023